Clinical application and research progress of remimazolam
10.12092/j.issn.1009-2501.2021.12.016
- Author:
Baowei JIN
1
;
Zongming JIANG
1
;
Jianrong GUO
2
Author Information
1. Department of Anesthesiology, Shaoxing People's Hospital
2. Department of Anesthesiology, Gongli Hospital, Naval Military Medical University
- Publication Type:Journal Article
- Keywords:
Calm;
General anesthesia;
Remimazolam
- From:
Chinese Journal of Clinical Pharmacology and Therapeutics
2021;26(12):1444-1448
- CountryChina
- Language:Chinese
-
Abstract:
Remimazolam is a new ultra-short-acting sedative, with rapid onset and recovery, metabolism independent of liver and kidney function, light respiratory inhibition, stable hemodynamics, long time application without accumulation. Carboxylic acid metabolites have no pharmacological effects, and can be rapidly reversed by antagonist flumazenil, which is expected to become a new choice of clinical sedative. In this paper, pharmacological characteristics and recent research progress of remimazolam are reviewed, which can provide reference for clinical safe drug use.
